Therapeutics for 'Silent' Cancers

Feb 2015| PHM169A| BCC Publishing

Report Highlights

The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual growth rate (CAGR) of 8.5% from 2014 to 2019.

Report Includes

  • An overview of the global markets and technologies for the therapeutics for "silent" cancers.
  • Analyses of global market trends, with data from 2013, 2014, and projections of CAGRs through 2019.
  • Descriptions of cancers, with incidence and prevalence data for all major national markets.
  • Assessments of currently available therapies.
  • Evaluation of new agents now in clinical development, with likely launch timetables and estimates of potential clinical value.
  • Profiles of major players in the "silent" cancer therapeutics industry.


The report discusses eight cancers described as “silent and deadly” because they are often undiagnosed until the diseases is advanced and difficult to treat. These cancers are brain, cervix, esophagus, mouth and larynx, ovary, pancreas, kidney, and lastly, liver. For each cancer, the cause, clinical course, diagnosis and treatment are described. Current drug therapy is outlined and new research activities are listed. The market is summarized and quantified for each cancer, with estimates of recent (2013) and current (2014) values for each cancer, and five-year projection to 2019. Geographically, the global market is given, with country analyses for the U.S., Japan, and five major Western European markets: Germany, France, Italy, Spain and the United Kingdom.


Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous reports on the cancer marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Frequently Asked Questions (FAQs)

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
. Title/Chapter NamePagesPrice Member Price
Full Report: Therapeutics for 'Silent' Cancers123 $2,750 Free
Chapter- 1: INTRODUCTION3Free
Chapter- 2: SUMMARY4$250Free
Chapter- 3: OVERVIEW7$157Free
Chapter- 4: BRAIN CANCER10$224Free
Chapter- 6: CANCER OF THE ESOPHAGUS6$134Free
Chapter- 7: LIVER CANCER7$157Free
Chapter- 8: RENAL CANCER8$179Free
Chapter- 9: CANCER OF THE PANCREAS9$201Free
Chapter- 10: CANCER OF THE CERVIX9$201Free
Chapter- 11: OVARIAN CANCER17$380Free
Chapter- 12: TUMOR MARKERS10$224Free
Chapter- 13: COMPANY PROFILES18$402Free
Chapter- 14: APPENDIX 1: GLOSSARY8$179Free
Therapeutics for 'Silent' Cancers

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries